Original Research Prim Care Companion CNS Disord March 2026

Efficacy and Tolerability of Ultra–Low-Dose Mirtazapine in Adult Chronic Insomnia

PCC CNS Disord 2026;28(2):10.4088/PCC.25m04074

Full Article Read the complete peer-reviewed article in Prim Care Companion CNS Disord. PCC CNS Disord 2026;28(2):10.4088/PCC.25m04074 Clinical Summary Chronic insomnia remains difficult to treat when cognitive-behavioral therapy for insomnia is contraindicated or when standard sleep medications have not worked. This study addresses a common real-world question in psychiatric practice: whether mirtazapine 3.75 mg offers a tolerable short-term option for treatment-resistant insomnia. FAQ What did this study find about mirtazapine 3.75 mg for chronic insomnia? 10 questions
Key Takeaways In this VA outpatient cohort, mirtazapine 3.75 mg was used after lack of efficacy with traditional sleep aids, supporting it as a practical next-step option for treatment-resistant insomnia rather than a first-line intervention. 5 takeaways Clinical Guide How should clinicians decide when to consider ultra-low-dose mirtazapine for adults with chronic insomnia? 5 steps Clinical Guide How should clinicians track short-term insomnia response after starting ultra-low-dose mirtazapine? 5 steps
Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen to the JCP Podcast Now
Figure: Digital illustration shows a human head with neural connections and podcast title over a dark blue patterned background.

Subscribe to read
more articles

Subscribe